Cresco Labs shareholders have overwhelmingly approved a series of corporate restructuring measures designed to position the marijuana company for a potential listing on a major U.S. stock exchange, including the creation of a new parent company and a possible relocation of its corporate domicile from Canada to Delaware.
The company announced November 2 that shareholders approved three special resolutions during its October 30 annual general and special meeting. Each measure received support from at least 94% of the shares voted, giving management broad authorization to pursue structural changes intended to simplify operations and expand access to U.S. capital markets.
The first resolution authorizes the creation of a new parent company, referred to as TopCo, which would become the publicly traded holding company for Cresco Labs. Existing Cresco securities and participating membership interests in Cresco Labs LLC would be exchanged for securities in the new entity, consolidating the company’s ownership structure.
The second resolution authorizes a potential subsequent relocation of TopCo from British Columbia to Delaware. Under the company’s previously announced plan, the board would have discretion to complete that move after establishing the new parent company, with the authorization extending through December 31, 2027.
Cresco said the relocation would make its corporate structure more familiar to American investors, align its legal domicile with its U.S. operations and potentially improve access to domestic capital markets.
The third approved measure extends the period during which the company’s multiple voting shares can remain outstanding following a U.S. stock exchange listing. Previously scheduled to expire on the first anniversary of such a listing, those shares would now remain in place until the third anniversary, allowing additional continuity in corporate governance during a potential transition.
In a September announcement outlining the proposals, Cresco Labs CEO Charles Bachtell said, “The proposals we are putting before shareholders are designed to position Cresco Labs for listing on a senior U.S. exchange.”
“Taken together, they streamline our corporate and capital structure while lowering administrative cost and complexity,” Bachtell said.
The restructuring plan also gives the board flexibility to implement a reverse stock split if necessary to satisfy the requirements of a major U.S. exchange. According to the company’s shareholder materials, the authorized consolidation ratio ranges from five to 15 existing shares for each new share.
Cresco Labs currently trades on the Canadian Securities Exchange under CL and on the U.S. OTCQX market under CRLBF. A listing on a major American exchange could provide greater access to institutional investors and potentially improve trading liquidity.
However, shareholder approval does not mean the restructuring has been completed or that a U.S. listing is imminent. The proposed transactions remain subject to applicable court, regulatory and stock exchange approvals, while the uncertain federal legal status of marijuana continues to complicate access to major American exchanges.
Alongside the restructuring resolutions, shareholders approved the election of seven directors, including Bachtell, Marc Lustig, Thomas J. Manning, Randy D. Podolsky, Michele Roberts, Robert M. Sampson and Edward Tilly. All seven received shareholder approval at the October 30 meeting.
The vote gives Cresco Labs additional flexibility to reorganize its corporate structure as the marijuana industry navigates changes in federal policy and the possibility of expanded access to traditional U.S. financial markets.
